Significant Investment in Peptide Manufacturing
CordenPharma has embarked on a remarkable journey, announcing an investment exceeding €1 billion in the enhancement of its peptide manufacturing capabilities. This strategic move will not only bolster the company’s stature as a leader in the sector but also ensure that it meets the burgeoning demand for innovative peptide-based medicines. The investment encompasses the establishment and expansion of various peptide manufacturing facilities across Europe and the U.S., with a keen focus on leveraging state-of-the-art technology and sustainable practices.
New Facility in Switzerland
One of the crowning achievements of this investment is the construction of a greenfield facility in Switzerland, particularly in the region of Muttenz. This state-of-the-art plant will facilitate the development and manufacturing of peptides at all scales, from small to large-scale production. The choice of location not only taps into Switzerland's rich ecosystem of biotech innovation but also optimizes logistics and ensures access to a highly skilled workforce.
Advantages of the Swiss Location
The strategic selection of Muttenz is supported by several compelling advantages. For starters, the area boasts an efficient infrastructure tailored for handling complex manufacturing processes essential for peptide production. Moreover, with streamlined access to transportation networks and established utilities, the site is poised for seamless operational efficiency.
Sustainable Practices and Technological Innovation
Apart from logistical and infrastructural benefits, the facility will embrace sustainability, operating within a well-established manufacturing ecosystem known for its focus on closed-loop energy and material cycles. CordenPharma is committed to a strategic path toward both economic and environmental sustainability, reinforcing its commitment to a net-zero vision while effectively addressing the rising demand for peptide medicines.
Capacity Expansion and Job Creation
The investment plan includes multiple manufacturing lines equipped with advanced Solid Phase Peptide Synthesis (SPPS) reactors. This setup allows for a remarkable capacity that exceeds 5,000 liters, suitable for both GLP-1 and non-GLP-1 peptide projects. This ambitious project is expected to create over 300 new jobs, contributing significantly to local economic growth and innovation. As the construction phase progresses through 2025 and 2027, commercial activities are anticipated to commence in the first half of 2028.
Continued Growth in the U.S.
The momentum of CordenPharma’s expansion does not stop at the Swiss border. In Boulder, Colorado, facility enhancements are already underway, targeting a significant increase in SPPS reactor capacity. By adding an additional 25,000 liters, the total reactor capacity in Colorado is expected to surpass 42,000 liters by 2028, reinforcing CordenPharma’s role as a major player in the contract development and manufacturing organization (CDMO) landscape.
Executive Insights
Dr. Michael Quirmbach, President & CEO of CordenPharma Group, expressed enthusiasm over the construction of the new facility near Basel. He highlighted the plant's design to cater to the increasing demand for peptide manufacturing, which aims to serve both clients and ultimately, the patients who depend on innovative therapeutic solutions.
Investment Support and Long-term Vision
Judith Charpentier from Astorg, the private equity firm that acquired CordenPharma in 2022, affirmed their support for CordenPharma’s growth. She emphasized the importance of combining industrial excellence with strategic investments to respond effectively to the escalating demand for peptide production. The expansion not only strengthens CordenPharma's market position but also enhances patient access to potentially life-saving peptide-based medicines.
About CordenPharma
CordenPharma stands as a pivotal CDMO partner, dedicated to supporting innovations in drug development. With a suite of bespoke outsourcing solutions, the company offers end-to-end services ranging from initial clinical-phase development to successful commercialization. CordenPharma's extensive network of integrated facilities spans across multiple geographic locations, enabling it to serve a diverse clientele effectively.
About Astorg
Astorg, a prominent pan-European private equity firm, manages more than €23 billion in assets. It partners with innovative management teams to empower market-leading companies in Europe and the U.S. through strategic oversight and capital investment, aiming for sustainable growth and industry leadership in various sectors including healthcare and technology.
Frequently Asked Questions
What is CordenPharma's recent investment strategy?
CordenPharma is investing over €1 billion in expanding its peptide manufacturing capabilities across Europe and the U.S.
Where is the new CordenPharma facility being built?
The new facility is being constructed in Muttenz, Switzerland, near Basel.
How will this investment affect local employment?
The construction of the new facility is expected to create over 300 new jobs in the area, contributing to local economic growth.
What is Solid Phase Peptide Synthesis (SPPS)?
SPPS is a method used to produce peptides in a solid phase environment, allowing for efficient synthesis of complex peptide sequences.
Who is Astorg, and how do they relate to CordenPharma?
Astorg is a pan-European private equity firm that supports CordenPharma's growth strategy following its acquisition in 2022.
